Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBT: 2018-2025

Historic EBT for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to -$17.7 million.

  • Whitehawk Therapeutics' EBT fell 41.06% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 67.25%. This contributed to the annual value of -$63.7 million for FY2024, which is 3.15% up from last year.
  • Latest data reveals that Whitehawk Therapeutics reported EBT of -$17.7 million as of Q3 2025, which was up 66.47% from -$52.8 million recorded in Q2 2025.
  • Whitehawk Therapeutics' EBT's 5-year high stood at -$1.5 million during Q2 2021, with a 5-year trough of -$87.1 million in Q3 2021.
  • In the last 3 years, Whitehawk Therapeutics' EBT had a median value of -$16.3 million in 2023 and averaged -$19.2 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' EBT slumped by 2,912.38% in 2021, and later surged by 83.38% in 2022.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' EBT stood at -$16.0 million in 2021, then increased by 12.93% to -$13.9 million in 2022, then fell by 16.86% to -$16.3 million in 2023, then fell by 12.32% to -$18.3 million in 2024, then tumbled by 41.06% to -$17.7 million in 2025.
  • Its EBT stands at -$17.7 million for Q3 2025, versus -$52.8 million for Q2 2025 and -$14.4 million for Q1 2025.